Skip to main content

Market Overview

Qualigen Files US Application To Start Human Trials For COVID-19 Candidate

Share:
Qualigen Files US Application To Start Human Trials For COVID-19 Candidate
  • Qualigen Therapeutics Inc (NASDAQ: QLGNhas submitted an Investigational New Drug (IND) application to the FDA for its QN-165 with an initial target indication of COVID-19 in hospitalized patients. 
  • QN-165, a DNA aptamer, is a broad-based antiviral drug candidate that has exhibited antiviral activity in multiple in vitro assays against different viruses.
  • Price Action: QLGN shares are up 10.1% at $1.96 during the premarket session on the last check Wednesday.
  • Related content: Benzinga's Full FDA Calendar.
 

Related Articles (QLGN)

View Comments and Join the Discussion!

Posted-In: Briefs Covid-19Biotech News Penny Stocks Health Care FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com